Epirus, Livzon in Asian biosimilar deal

Epirus Biopharmaceuticals Inc. (NASDAQ:EPRS) partnered with Livzon Mabpharm Inc. (Zhuhai City, China) to develop, manufacture and commercialize up to five biosimilar antibodies in Asia. The deal includes Infimab infliximab (formerly BOW015), Epirus' biosimilar of Remicade infliximab from Johnson & Johnson (NYSE:JNJ) and Merck & Co. Inc. (NYSE:MRK).

Epirus said Livzon will conduct development work for Chinese and Taiwanese approval of Infimab and be the preferred supplier to China and Taiwan. Epirus did not reply to an inquiry concerning which, if any, other Asian markets the deal covers. Livzon is responsible for all commercialization in territories covered by the deal. Epirus is eligible for undisclosed royalty payments. ...